AbbVie (ABBV) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $283.40, -0.03% vs the prior close of $283.48.
- Volume 7.62M shares, 1.7x its 50-day average.
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
ABBV ends flat (-0.0%) to $283.40. Closed at $283.40, -0.03% vs the prior close of $283.48. Day range $282.81–$291.40, opened at $288.28.
ABBV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ABBV ends flat (-0.0%) to $283.40
- Closed at $283.40, -0.03% vs the prior close of $283.48. Day range $282.81–$291.40, opened at $288.28.
- Volume was 7.62M shares, 1.7x its 50-day average of 4.53M.
- Price is +8.3% vs its 50-day average ($261.62) and +21.3% vs its 200-day average ($233.67).
- 52-week range $190.75–$291.40; today's close sits at 92% of that range, 2.7% below the 52-week high.
- SEC filings that day: 8-K.
Oct 14, 2026 — ABBV jumps 3.3% to $283.48, a 52-week high
- Closed at $283.48, +3.32% vs the prior close of $274.36. Day range $275.97–$285.40, opened at $277.00.
- Volume was 5.62M shares, 1.2x its 50-day average of 4.58M.
- Price is +8.7% vs its 50-day average ($260.88) and +21.5% vs its 200-day average ($233.40).
- 52-week range $190.75–$285.40; today's close sits at 98% of that range, 0.7% below the 52-week high.
Oct 13, 2026 — ABBV dips 2.4% to $274.36
- Closed at $274.36, -2.40% vs the prior close of $281.12. Day range $273.70–$283.43, opened at $283.29.
- Volume was 6.41M shares, 1.4x its 50-day average of 4.60M.
- Price is +5.5% vs its 50-day average ($260.08) and +17.7% vs its 200-day average ($233.14).
- 52-week range $190.75–$283.43; today's close sits at 90% of that range, 3.2% below the 52-week high.
Oct 12, 2026 — ABBV rises 1.7% to $281.12, a 52-week high, 7 up days in a row
- Closed at $281.12, +1.68% vs the prior close of $276.47. Day range $276.01–$281.30, opened at $277.65.
- Volume was 5.59M shares, 1.2x its 50-day average of 4.63M.
- Price is +8.3% vs its 50-day average ($259.50) and +20.7% vs its 200-day average ($232.91).
- 52-week range $190.75–$281.30; today's close sits at 100% of that range, 0.1% below the 52-week high.
- That makes 7 straight gains.
Oct 9, 2026 — ABBV rises 1.5% to $276.47, a 52-week high, 6 up days in a row
- Closed at $276.47, +1.49% vs the prior close of $272.42. Day range $270.38–$277.60, opened at $271.53.
- Volume was 4.30M shares, 0.9x its 50-day average of 4.67M.
- Price is +6.8% vs its 50-day average ($258.89) and +18.8% vs its 200-day average ($232.65).
- 52-week range $190.75–$277.60; today's close sits at 99% of that range, 0.4% below the 52-week high.
- That makes 6 straight gains.
Oct 8, 2026 — ABBV rises 0.4% to $272.42, a 52-week high, 5 up days in a row
- Closed at $272.42, +0.39% vs the prior close of $271.36. Day range $265.71–$272.52, opened at $270.98.
- Volume was 5.49M shares, 1.2x its 50-day average of 4.68M.
- Price is +5.4% vs its 50-day average ($258.51) and +17.2% vs its 200-day average ($232.41).
- 52-week range $190.75–$274.94; today's close sits at 97% of that range, 0.9% below the 52-week high.
- That makes 5 straight gains.
Oct 7, 2026 — ABBV rises 1.8% to $271.36, a 52-week high, 4 up days in a row
- Closed at $271.36, +1.75% vs the prior close of $266.69. Day range $266.89–$274.94, opened at $268.40.
- Volume was 6.08M shares, 1.3x its 50-day average of 4.70M.
- Price is +5.0% vs its 50-day average ($258.33) and +16.9% vs its 200-day average ($232.18).
- 52-week range $190.75–$274.94; today's close sits at 96% of that range, 1.3% below the 52-week high.
- That makes 4 straight gains.
Oct 6, 2026 — ABBV rises 0.3% to $266.69, a 52-week high, 3 up days in a row
- Closed at $266.69, +0.35% vs the prior close of $265.76. Day range $260.62–$268.86, opened at $267.74.
- Volume was 4.50M shares, 1.0x its 50-day average of 4.71M.
- Price is +3.3% vs its 50-day average ($258.17) and +15.0% vs its 200-day average ($231.94).
- 52-week range $190.75–$269.39; today's close sits at 97% of that range, 1.0% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — ABBV rises 1.1% to $265.76
- Closed at $265.76, +1.12% vs the prior close of $262.82. Day range $260.29–$267.34, opened at $261.27.
- Volume was 7.54M shares, 1.6x its 50-day average of 4.65M.
- Price is +3.0% vs its 50-day average ($257.97) and +14.7% vs its 200-day average ($231.73).
- 52-week range $190.75–$269.39; today's close sits at 95% of that range, 1.3% below the 52-week high.
- SEC filings that day: 8-K.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 2, 2026 — ABBV rises 1.1% to $262.82
- Closed at $262.82, +1.11% vs the prior close of $259.93. Day range $257.87–$264.06, opened at $259.74.
- Volume was 5.86M shares, 1.3x its 50-day average of 4.62M.
- Price is +1.9% vs its 50-day average ($257.84) and +13.5% vs its 200-day average ($231.52).
- 52-week range $190.75–$269.39; today's close sits at 92% of that range, 2.4% below the 52-week high.
ABBV latest news & SEC filings
Every SEC filing by or about ABBV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 18, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Donoghoe Nicholas sold 32,710 shares at $250.00 (≈$8.18M) on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 5, 2026 · FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 4, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 3, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $16.99B (prior year $15.42B) (+10.2% vs Jun 30, 2025)
- Net income: $3.61B (prior year $938.00M) (+285.2% vs Jun 30, 2025)
- Diluted EPS: $2.03 (prior year $0.52) (+290.4% vs Jun 30, 2025)
Jul 31, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ABBV
- Last results release: Oct 5, 2026 (8-K Item 2.02). Previous ones: Jul 31, 2026, Jul 6, 2026, Apr 29, 2026. Based on that rhythm, the next report is likely around Jan 4, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 0.88% (largest 3.3%). That is a relatively calm stock.
- Liquidity: about 4.98M shares (≈$1.41B) trade per day on average.
- 52-week position: $283.40 vs a range of $190.75–$291.40 (92% of the range).
- Dividends: last ex-dividend date Oct 15, 2026 ($1.73/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 6 sales; latest: Nicholas Donoghoe sold 32,710 shares on Aug 14, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Oct 5, 2026; 8-K Sep 3, 2026.
- Share count: 1.77B shares outstanding (Jul 27, 2026), +0.0% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
ABBV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 288.28 | 291.40 | 282.81 | 283.40 | 7.62M |
| Oct 14, 2026 | 277.00 | 285.40 | 275.97 | 283.48 | 5.62M |
| Oct 13, 2026 | 283.29 | 283.43 | 273.70 | 274.36 | 6.41M |
| Oct 12, 2026 | 277.65 | 281.30 | 276.01 | 281.12 | 5.59M |
| Oct 9, 2026 | 271.53 | 277.60 | 270.38 | 276.47 | 4.30M |
| Oct 8, 2026 | 270.98 | 272.52 | 265.71 | 272.42 | 5.49M |
| Oct 7, 2026 | 268.40 | 274.94 | 266.89 | 271.36 | 6.08M |
| Oct 6, 2026 | 267.74 | 268.86 | 260.62 | 266.69 | 4.50M |
| Oct 5, 2026 | 261.27 | 267.34 | 260.29 | 265.76 | 7.54M |
| Oct 2, 2026 | 259.74 | 264.06 | 257.87 | 262.82 | 5.86M |
| Oct 1, 2026 | 260.51 | 262.32 | 259.00 | 259.93 | 3.89M |
| Sep 30, 2026 | 264.60 | 265.36 | 261.59 | 261.59 | 4.39M |
| Sep 29, 2026 | 265.45 | 268.93 | 261.52 | 263.29 | 4.00M |
| Sep 28, 2026 | 264.33 | 267.74 | 263.38 | 266.28 | 4.42M |
| Sep 25, 2026 | 265.49 | 266.00 | 262.59 | 264.34 | 2.54M |
| Sep 24, 2026 | 265.37 | 267.41 | 263.09 | 265.12 | 3.46M |
| Sep 23, 2026 | 266.00 | 269.39 | 263.59 | 265.08 | 3.47M |
| Sep 22, 2026 | 263.10 | 266.82 | 262.15 | 265.21 | 2.77M |
| Sep 21, 2026 | 263.07 | 266.60 | 261.23 | 264.48 | 3.43M |
| Sep 18, 2026 | 263.29 | 266.34 | 262.44 | 263.96 | 8.18M |
About AbbVie
AbbVie (ABBV) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NORTH CHICAGO, IL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1551152.
ABBV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Roxanne S Austin | Director | May 12, 2026 |
| Robert J Alpern | Director | Apr 2, 2026 |
| William H.L. Burnside | Director | May 12, 2026 |
| Jennifer L. Davis | Director | May 12, 2026 |
| Thomas J Falk | Director | May 12, 2026 |
| Thomas C Freyman | Director | May 12, 2026 |
| Brett J Hart | Director | May 12, 2026 |
| Melody B Meyer | Director | May 12, 2026 |
| Robert A. Michael | CHAIRMAN OF THE BOARD AND CEO | Mar 3, 2026 |
| Susan E Quaggin | Director | Jul 2, 2026 |
| Edward J Rapp | Director | Jul 2, 2026 |
| Rebecca B Roberts | Director | May 12, 2026 |
| Frederick H Waddell | Director | May 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Demetris D Crum | EVP, CHIEF HR OFFICER | Mar 6, 2026 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | Aug 18, 2026 |
| Robert A. Michael | CHAIRMAN OF THE BOARD AND CEO | Mar 3, 2026 |
| David Ryan Purdue | SVP, Controller | Mar 11, 2026 |
| Scott T Reents | EVP, CHIEF FINANCIAL OFFICER | Mar 3, 2026 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | Mar 3, 2026 |
| Perry C Siatis | EVP, GC AND SECRETARY | Mar 3, 2026 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Mar 3, 2026 |
| Roopal Thakkar | EVP, R&D and CSO | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Nicholas Donoghoe | Sale | 32,710 | $250.00 |
| Mar 4, 2026 | David Ryan Purdue | Sale | 5,230 | $233.56 |
| Mar 2, 2026 | Perry C Siatis | Sale | 10,291 | $234.66 |
| Mar 2, 2026 | Perry C Siatis | Sale | 2,600 | $235.26 |
| Mar 2, 2026 | Perry C Siatis | Sale | 5,777 | $233.51 |
| Feb 25, 2026 | Perry C Siatis | Sale | 22,381 | $230.00 |
ABBV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $61.16B | $4.23B | 2.36 | $19.03B |
| Dec 31, 2024 | $56.33B | $4.28B | 2.39 | $18.81B |
| Dec 31, 2023 | $54.32B | $4.86B | 2.72 | $22.84B |
| Dec 31, 2022 | $58.05B | $11.84B | 6.63 | $24.94B |
| Dec 31, 2021 | $56.20B | $11.54B | 6.45 | $22.78B |
Latest balance sheet: total assets $135.12B, total liabilities $—, cash $6.57B (as of Jun 30, 2026).
ABBV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 5, 2026 | 8-K Item 2.02 (results) | $265.76 |
| Jul 31, 2026 | 8-K Item 2.02 (results) | $250.94 |
| Jul 6, 2026 | 8-K Item 2.02 (results) | $254.76 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $203.89 |
| Apr 3, 2026 | 8-K Item 2.02 (results) | $206.69 |
| Feb 4, 2026 | 8-K Item 2.02 (results) | $217.11 |
| Jan 7, 2026 | 8-K Item 2.02 (results) | $233.42 |
| Oct 31, 2025 | 8-K Item 2.02 (results) | $218.04 |
| Oct 3, 2025 | 8-K Item 2.02 (results) | $233.91 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $189.02 |
| Jul 3, 2025 | 8-K Item 2.02 (results) | $189.28 |
| Apr 25, 2025 | 8-K Item 2.02 (results) | $186.06 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ABBV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.